AN2 Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $80 | $80 |
Gross Profit | 40 | 40 | ||
EBITDA | -11,771 | -15,880 | -16,201 | -18,815 |
EBIT | -14,014 | -31,760 | -35,016 | -18,833 |
Net Income | -12,747 | -14,435 | -16,617 | -16,898 |
Net Change In Cash | 0 | 0 | 80 | 80 |
Free Cash Flow | -12,007 | -14,384 | -17,593 | -17,068 |
Cash | 33,504 | 26,769 | 24,693 | 15,647 |
Basic Shares | 29,841 | 29,824 | 29,763 | 29,735 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -77 | |||
EBITDA | 4,903 | -43,468 | -21,474 | -7,284 |
EBIT | -64,732 | -42,262 | -21,574 | -7,284 |
Net Income | -64,732 | -41,470 | -21,474 | -13,600 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -53,288 | -33,462 | -20,484 | -5,364 |
Cash | 15,647 | 27,219 | 12,097 | 4,070 |
Basic Shares | 23,600 | 19,402 | 18,739 | 18,739 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.35 |
2024-06-30 | -$0.48 |
2024-03-31 | -$0.56 |
2023-12-31 | -$0.57 |
